Emily Edson-Heredia

Emily Edson-Heredia

Eli Lilly And Company, Lilly Corporate Center, 46285, Indianapolis, In, Usa

Direct Impact

Concepts for which Emily Edson-Heredia has direct influence:

alopecia areata
plaque psoriasis
touch avoidance
content validity
biologic therapy
psoriatic arthritis
itch severity

External impact

Concepts related to the work of other authors for which Emily Edson-Heredia has influence:

alopecia areata
pediatric psoriasis
onset age
scalp hair
joint american
atopic dermatitis
psychiatric disorders

Prominent publications by Emily Edson-Heredia

KOL-Index: 255 BACKGROUND: Itch is a prevalent symptom of psoriasis that impacts quality of life. OBJECTIVE: We sought to describe improvements in itch severity, skin pain, and bothersomeness of skin appearance caused by psoriasis among patients who received ixekizumab, etanercept, or placebo in three 12-week, phase III clinical trials (UNCOVER-1, -2, and -3). METHODS: The itch numeric rating scale ...
Known for
Psoriasis Ixekizumab | Flaking | Improvements Itch | Assessed Skin
KOL-Index: 95 IntroductionThere are limited real-world data on treatment patterns, comorbidities, and healthcare burden in pediatric patients with psoriasis. We examined patient demographics, comorbidity burden, treatment patterns, and healthcare use and costs in pediatric psoriasis.MethodsA retrospective, real-world, exploratory study was conducted using US claims databases. Pediatric patients ...
Known for
Utilization Costs | Claims Comorbidity | Post Demographics | Comorbidities Observed
KOL-Index: 46 Psoriasis treatment responses are affected by patient characteristics. However, the literature does not contain reviews of factors that affect the response to biologic therapies. We therefore performed a comprehensive literature search to identify papers describing demographic, lifestyle, and clinical factors associated with response to biologic drug therapy in psoriatic patients. We found ...
Known for
Psoriasis Therapy | Affect Responses
KOL-Index: 30 INTRODUCTION: The content validity and treatment success thresholds of clinical outcome assessments (COAs) for alopecia areata (AA)-including the Alopecia Areata-Investigator Global Assessment™ (AA-IGA™), Scalp Hair Assessment Patient-Reported Outcome™ (PRO), and clinician-reported outcome (ClinRO) and PRO measures for eyebrows, eyelashes, eye irritation, and nails-were established in ...
Known for
Loss Interviews | Hair Coas | Thematic Framework Techniques | Alopecia Areata-Investigator
KOL-Index: 30 INTRODUCTION: Alopecia areata (AA) is an autoimmune disorder causing sudden, non-scarring hair loss. There are currently no drugs approved for AA treatment. This study assessed prevalence of comorbidities, treatments, and healthcare costs and resource utilization among patients with AA in the USA. METHODS: Patients diagnosed with AA between January 2011 and December 2018 were identified in ...
Known for
Identified Claims | Areata | Prescribed Comorbid | Conditions Treatments
KOL-Index: 23 Background: Psoriasis is a chronic inflammatory skin disease.Objective: To establish content validity and assess psychometric properties of the Psoriasis Symptoms Scale (PSS) in patients with moderate-to-severe psoriasis (Ps).Methods: The PSS is an eight-item patient-completed questionnaire assessing symptoms (itch, pain, stinging, burning), signs (redness, scaling, cracking), and ...
Known for
Test-Retest Reliability | Itch | Burning | Redness
KOL-Index: 19 BACKGROUND: Previous studies have associated alopecia areata (AA) with a number of comorbidities. However, the timing between AA and the development of such comorbidities remains poorly understood. AIM: To examine the temporal relationship between AA diagnosis and comorbidity development in Denmark. METHODS: A Danish nationwide register-based cohort study was performed on all individuals ...
Known for
Thyroid Irr | Areata | Frequently Diagnosis | Asthma Comorbidities
KOL-Index: 16 BACKGROUND: There are no treatments approved by the Food and Drug Administration for alopecia areata. OBJECTIVE: To evaluate the efficacy and safety of baricitinib in patients with ≥50% scalp hair loss in a phase 2 study of adults with alopecia areata (BRAVE-AA1). METHODS: Patients were randomized 1:1:1:1 to receive placebo or baricitinib 1 mg, 2 mg, or 4 mg once daily. Two consecutive ...
Known for
Brave-Aa1 | 2-Mg | Lower Salt30 Response Rate | Food Drug
KOL-Index: 15 BACKGROUND: In patients with moderate-to-severe psoriasis, health-related quality of life (HRQOL) has been shown to improve in parallel with improvement in disease severity. OBJECTIVES: To evaluate the role of pruritus (itch) in mediating the relationship between improvements in disease severity and HRQOL. METHODS: Data from a phase 2 clinical trial, in which 142 patients with ...
Known for
Improvement Pasi | Posthoc | Psoriasis Area | Ixekizumab

Eli Lilly and Company, Lilly Corporate Center, 46285, Indianapolis, IN, USA

https://www.g2.com/products/key-opinion-leaders-kols/reviews https://www.bbb.org/us/fl/doral/profile/data-analytics/key-opinion-leaders-0633-92023858 https://www.trustpilot.com/review/keyopinionleaders.com https://www.yelp.com/biz/key-opinion-leaders-miami

© 2022 - Key Opinion Leaders -
Key Opinion Leaders, LLC ,
2025 NW 102 Avenue, Suite 111 Doral , FL   33172